Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.33 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.33 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996151 | 0.85 | ADORA1 (0.35) | ADORA1NT5ECARM1ADCY5 | |
| SCHEMBL2483149 | 0.74 | P2RY12 (0.35) | — | |
| SCHEMBL31645122 | 0.71 | ADORA1 (0.45) | ADORA1NT5EAHCYADORA3 | |
| SCHEMBL15996150 | 0.70 | TYMP (0.53) | ADORA1NT5ECARM1 | |
| SCHEMBL9705275 | 0.69 | ADORA3 (0.46) | ADORA1DOT1LADORA3ADORA2B | |
| SCHEMBL1068569 | 0.68 | ADORA1 (0.44) | ADORA1CARM1DOT1LADORA3ADORA2B | |
| SCHEMBL7029674 | 0.68 | ADORA1 (0.44) | ADORA1NT5EAHCYADORA3 | |
| SCHEMBL5859569 | 0.67 | PI4KA (0.43) | ADORA1DOT1LADORA3ADORA2B | |
| SCHEMBL17428139 | 0.67 | ADORA1 (0.59) | ADORA1DOT1LADORA3ADORA2B | |
| SCHEMBL10381790 | 0.66 | ADORA1 (0.43) | ADORA1DOT1LADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961757-B1 | CELL-PENETRATING OLIGONUCLEOTIDES | OLIGOMER SCIENCES AB (SE) | 2017-06-14 | — | — | EP | disclosed |
| US-9463200-B2 | Cell-penetrating oligonucleotides | OLIGOMER SCIENCES AB (SE) | 2016-10-11 | — | — | US | disclosed |
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | ASTRAZENECA AB (SE) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008389-A1 | Cell-Penetrating Oligonucleotides | SLC29A1, SLC29A2, TYMP | ADORA1 8/4885NT5E 9/4885CARM1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.